RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca • ClinicalTrials.gov ID: NCT06137118

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization and efficacy expansion in R/R B-ALL (2L+)

Interventions

Surovatamig (Drug)
Investigational Product administered via intravenous infusion.

Eligibility criteria

Inclusion Criteria: * Age: 12 years and above (Parts A, B, C and D). * Participants with B-cell Acute Lymphoblastic Leukemia with CD19 expression by local lab with: 1. Bone marrow infiltration with \>/= 5% blasts 2. Either relapsed or refractory after a minimum of 2 prior therapies or after 1 prior line of therapy if no SOC available option (Parts A, B, C); or relapsed or refractory to ≥1 prior line of therapy (Part D). 3. Philadelphia positive participants are allowed in all parts of the study, if intolerant or refractory to TKIs. * For participants older than 16 years, Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. For Participants 16 years or younger, Lansky score more or equal to 50%. The above is a summary, other inclusion criteria details may apply. Exclusion Criteria: * Active CNS involvement by B-ALL, defined by presence of ALL blasts in CSF (CNS2 and CNS3 criteria), or signs of CNS involvement. * Isolated extramedullary disease relapse. * Testicular leukemia * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis; or prior Grade 4 neurotoxicity with CAR-T or TCE therapy. * History of other malignancy (with certain exceptions). * Unresolved AEs \>/= Grade 2, from prior therapies * Prior therapy with ADCs within 3 weeks, TCEs within 4 weeks, CAR T-cell therapy or autologous HSCT within 8 weeks or prior alloSCT within 12 weeks of start of therapy. * GVHD requiring immunosuppressive therapy within 3 weeks prior to AZD0486 treatment. The above is a summary, other exclusion criteria details may apply.

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Locations

Research Site — Birmingham, Alabama, United States
Research Site — Duarte, California, United States
Research Site — Los Angeles, California, United States
Research Site — Palo Alto, California, United States
Research Site — Tampa, Florida, United States
Research Site — Atlanta, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — New York, New York, United States
Research Site — Houston, Texas, United States
Research Site — Richmond, Virginia, United States
Research Site — Seattle, Washington, United States
Research Site — Milwaukee, Wisconsin, United States
Research Site — Melbourne, Australia
Research Site — Porto Alegre, Brazil
Research Site — São Paulo, Brazil
Research Site — São Paulo, Brazil
Research Site — Toronto, Ontario, Canada
Research Site — Montreal, Quebec, Canada
Research Site — Montreal, Quebec, Canada
Research Site — Changsha, China
Research Site — Chengdu, China
Research Site — Guangzhou, China
Research Site — Guangzhou, China
Research Site — Hangzhou, China
Research Site — Nanjing, China
Research Site — Nanjing, China
Research Site — Suzhou, China
Research Site — Tianjin, China
Research Site — Zhengzhou, China
Research Site — Caen, France
Research Site — Marseille, France
Research Site — Nantes, France
Research Site — Paris, France
Research Site — Pierre-Bénite, France
Research Site — Toulouse, France
Research Site — Berlin, Germany
Research Site — Cologne, Germany
Research Site — Düsseldorf, Germany
Research Site — Essen, Germany
Research Site — Frankfurt, Germany
Research Site — Freiburg im Breisgau, Germany
Research Site — Halle, Germany
Research Site — Hamburg, Germany
Research Site — Kiel, Germany
Research Site — München, Germany
Research Site — Münster, Germany
Research Site — Würzburg, Germany
Research Site — Bergamo, Italy
Research Site — Bologna, Italy
Research Site — Monza, Italy
Research Site — Naples, Italy
Research Site — Roma, Italy
Research Site — Bunkyō City, Japan
Research Site — Chiba, Japan
Research Site — Chūōku, Japan
Research Site — Fukuoka, Japan
Research Site — Kashiwa, Japan
Research Site — Kyoto, Japan
Research Site — Okayama, Japan
Research Site — Osaka, Japan
Research Site — Sapporo, Japan
Research Site — Toyohashi, Japan
Research Site — Yamagata, Japan
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea
Research Site — Barcelona, Spain
Research Site — Barcelona, Spain
Research Site — Madrid, Spain
Research Site — Madrid, Spain
Research Site — Salamanca, Spain
Research Site — Seville, Spain
Research Site — Valencia, Spain
Research Site — Kaohsiung City, Taiwan
Research Site — Taichung, Taiwan
Research Site — Tainan, Taiwan
Research Site — Taipei, Taiwan
Research Site — Taoyuan, Taiwan
Research Site — London, United Kingdom
Research Site — Manchester, United Kingdom
Research Site — Surrey, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment